乳腺癌的新辅助化疗后,残留的增殖性癌症负担能预测长期结果吗?

乳腺癌的新辅助化疗后,残留的增殖性癌症负担能预测长期结果吗?

相关实验视频

Updated: May 21, 2025

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

196

Imen Zawati¹, Yousra Troujette², Olfa Adouni¹

¹Department of Immuno-Histo-Cytology, Salah Azaiez Institute, Tunis, Tunisia; Department of Biology, Laboratory of Biochemistry and Molecular Biology, Faculty of Sciences of Tunis, University of Tunis El Manar, Ariana, Tunisia.

Pathology

|March 22, 2025

概括

剩余癌症负担 (RCB) 和剩余扩散性癌症负担 (RPCB) 预测新辅助化疗 (NACT) 后乳腺癌的结果. RPCB可能会改进RCBII病例的预后,但需要进行更大规模的研究来验证.

科学领域:

在瘤学瘤学.
乳腺癌研究研究乳腺癌研究
化疗疗的有效性化疗的有效性

背景情况:

其余癌症负担 (RCB) 是接受新辅助化疗 (NACT) 的乳腺癌患者长期结果的关键预测因素.
在NACT后评估残留疾病对于完善预后模型和指导治疗决策至关重要.

研究的目的:

为了比较多个NACT后分类对乳腺癌残留疾病评估的预后价值.
评估解剖学RCB指数和治疗后Ki-67增殖指数 (RPCB) 的综合预后影响.

主要方法:

分析了97名初级乳腺癌患者使用NACT.治疗的手术样本档案.
通过免疫组织化学和RCB和RPCB分数的计算量化术后Ki-67指数.
卡普兰-梅尔法和考克斯比例危险模型用于评估无复发生存率 (RFS) 和整体生存率.

主要成果:

RCBIII表示预后不佳 (5年RFS38%),而RCBI和病理完整响应 (RCB0) 显示出良好预后 (80%和100%RFS).
较高的NACT后Ki-67 (>20%) 对整体存活率和RFS (p<0.0001) 有负面影响.
与RPCBI (83%) 相比,RPCBIII显示出最差的预后 (5年RFS38%) (p=0.039).与RPCBI (83%) 相比,RPCBIII显示出最差的预后 (5年RFS38%).

结论:

瑞银指数仍然是RFS的独立预后因素.
在RCBII病例中,RPCB分类显示了分层预后的潜力.
需要在更大的队列中进一步验证,以确认RPCB在残留疾病评估中的附加值.

关键词:

乳腺癌乳腺癌乳腺癌新辅助性化疗是一种新辅助性化疗.预后预后预后癌症残留负担的癌症负担这种残留疾病的残留疾病是残留疾病.剩余的癌症扩散负担

更多相关视频

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

07:45

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

5.9K

Establishing a Competing Risk Regression Nomogram Model for Survival Data

04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.1K

相关概念视频

01:21

Cancer Survival Analysis

315

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

315

02:40

Cancer Stem Cells and Tumor Maintenance

4.7K

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...

4.7K

02:07

Tumor Progression

6.2K

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...